Charles Schwab
PROK icon

Charles Schwab’s ProKidney PROK Stock Holding History

Charles Schwab’s Portfolio PROK Stock Details PROK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.12M Buy
627,771
+4,661
+0.7% +$9.89K ﹤0.01% 2868
2025
Q4 		$1.4M Sell
623,110
-29,981
-5% -$78.8K ﹤0.01% 2826
2025
Q3 		$1.58M Buy
653,091
+93,297
+17% +$248K ﹤0.01% 2809
2025
Q2 		$331K Sell
559,794
-265,853
-32% -$207K ﹤0.01% 3282
2025
Q1 		$723K Buy
825,647
+65,860
+9% +$91.4K ﹤0.01% 2955
2024
Q4 		$1.28M Buy
759,787
+10,069
+1% +$18.2K ﹤0.01% 2824
2024
Q3 		$1.44M Buy
749,718
+450,548
+151% +$1.02M ﹤0.01% 2802
2024
Q2 		$736K Buy
299,170
+39,358
+15% +$106K ﹤0.01% 3036
2024
Q1 		$426K Buy
259,812
+4,709
+2% +$6.92K ﹤0.01% 3085
2023
Q4 		$454K Sell
255,103
-13,642
-5% -$29.3K ﹤0.01% 3112
2023
Q3 		$1.23M Buy
268,745
+121,963
+83% +$1.17M ﹤0.01% 2734
2023
Q2 		$1.64M Buy
+146,782
New +$1.56M ﹤0.01% 2608

Other funds holding PROK

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
AGP
Artia Global Partners Miami, Florida $499M AUM 186.05% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Charles Schwab's PROK Position: Q1 2026 in Review

Charles Schwab increased its ProKidney (PROK) stake by 0.75% in Q1 2026, buying an estimated $9.89K and bringing the position to 627,771 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #2868.

Charles Schwab first reported a position in PROK in Q2 2023 and has held it in 12 quarters since. The position peaked at $1.64M in Q2 2023. 71 funds tracked by Wall St. Rank hold PROK as of Q1 2026.

  • Charles Schwab held 627,771 shares of ProKidney worth $1.12M as of Q1 2026.
  • Charles Schwab bought 4,661 ProKidney shares in Q1 2026, an estimated $9.89K.
  • ProKidney made up ﹤0.01% of Charles Schwab's portfolio in Q1 2026, its #2868 holding.
  • Charles Schwab first reported a position in ProKidney in Q2 2023 and has held it in 12 quarters since.
  • Charles Schwab's ProKidney position peaked at $1.64M in Q2 2023.
  • 71 funds tracked by Wall St. Rank held ProKidney as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.